Patents Assigned to Laboratorios Bago S.A.
-
Patent number: 11090277Abstract: Pharmaceutical composition of memantine for administering orally which comprises a premixture comprising: i) between 74 and 85% w/w total of the premixture of a granulate of pellets comprising memantine between 10 and 15% w/w total of the premixture; coated by first coating of polyvinylpyrrolidone and a second coating comprising between 80 and 95% w/w total of the coating of cationic copolymer of dimethylaminoethyl methacrylate, butyl methacrylate and methyl methacrylate and between 5 and 20% w/w total of the coating of magnesium stearate; ii) between 4 and 7% w/w total of the premixture of sucralose; iii) between 11 and 19% w/w total of the premixture of essences. All the components have a particle size smaller than 710 microns. The composition can be a suspension, a powder for preparing a suspension or an oral disintegrating tablet. It can also be used to be administered through a nasogastric tube.Type: GrantFiled: December 23, 2015Date of Patent: August 17, 2021Assignees: LABORATORIOS BAGĂ“ S.A., Eastbrand Holding GMBHInventor: Mario Atilio Los
-
Patent number: 10786458Abstract: Procedure for preparing enteric-coated pellets containing a proton pump inhibitor with benzimidazole structure, useful for preparing multi-particle pharmaceutical compositions for oral use that comprises the following stages: I) coat pure cellulose cores with a hydroalcoholic suspension that contains the proton pump inhibitor, a dibasic amino acid and polyvinylpyrrolidone; II) isolate the coated pure cellulose cores obtained in Stage I; III) apply an enteric coating to the particles obtained in Stage II above; and IV) dry the particles obtained in Stage III above and separate by size.Type: GrantFiled: March 31, 2015Date of Patent: September 29, 2020Assignees: Laboratorios Bago S.A., Eastbrand Holding GMBHInventor: Mario Atilio Los
-
Patent number: 9918941Abstract: Method for producing enteric microcapsules without coating, containing diclofenac or one of the salts thereof with satisfactory anti-inflammatory activity and low gastric aggressiveness; and a pharmaceutical composition containing them. The method comprises a) preparing a mixture in water-ethanol with an alginate salt, adding diclofenac or one of the salts thereof previously diluted with a surfactant and sodium bicarbonate; b) adding the previous solution to a solution with a calcium salt; c) resuspending the microcapsules obtained and isolated in an aqueous solution of the alginate salt; and d) isolating, drying and sieving through 1000 and 250 micron meshes the microcapsules obtained; and selecting the fraction comprised between both meshes. The pharmaceutical composition can be an oral composition, tablets, chewable tablets, or a powder for suspension in water.Type: GrantFiled: March 9, 2017Date of Patent: March 20, 2018Assignees: Laboratorios Bago S.A., Eastbrand Holding GMBHInventor: Mario Atilio Los
-
Patent number: 9668978Abstract: Method for producing enteric microcapsules without coating, containing diclofenac or one of the salts thereof with satisfactory anti-inflammatory activity and low gastric aggressiveness; and a pharmaceutical composition containing them. The method comprises a) preparing a mixture in water-ethanol with an alginate salt, adding diclofenac or one of the salts thereof previously diluted with a surfactant and sodium bicarbonate; b) adding the previous solution to a solution with a calcium salt; c) resuspending the microcapsules obtained and isolated in an aqueous solution of the alginate salt; and d) isolating, drying and sieving through 1000 and 250 micron meshes the microcapsules obtained; and selecting the fraction comprised between both meshes. The pharmaceutical composition can be an oral composition, tablets, chewable tablets, or a powder for suspension in water.Type: GrantFiled: March 20, 2012Date of Patent: June 6, 2017Assignees: Laboratorios Bago S.A., Eastbrand Holding GmbHInventor: Mario Atilio Los
-
Patent number: 9308212Abstract: Disclosed is a composition comprising alprazolam for treating primary insomnia and insomnia associated with anxiety states and the corresponding use and method comprising the administration of alprazolam sublingual tablets having a disintegration time lower than 30 seconds and having the alprazolam preferably in non-crystalline or partially crystalline form according to the X-ray diffraction crystallography expanded for the position delta 9-12.5 (2 theta), to a patient suffering from said disorder. There is also disclosed a method for preparing a composition according to the invention, where the alprazolam is solved in a pharmaceutical acceptable solvent and a binder, preferably polyvinylpyrrolidone, is incorporated to the solution.Type: GrantFiled: December 11, 2013Date of Patent: April 12, 2016Assignee: LABORATORIOS BAGO S.A.Inventor: Mario Atilio Los
-
Publication number: 20150072000Abstract: Method for producing enteric microcapsules without coating, containing diclofenac or one of the salts thereof with satisfactory anti-inflammatory activity and low gastric aggressiveness; and a pharmaceutical composition containing them. The method comprises a) preparing a mixture in water-ethanol with an alginate salt, adding diclofenac or one of the salts thereof previously diluted with a surfactant and sodium bicarbonate; b) adding the previous solution to a solution with a calcium salt; c) resuspending the microcapsules obtained and isolated in an aqueous solution of the alginate salt; and d) isolating, drying and sieving through 1000 and 250 micron meshes the microcapsules obtained; and selecting the fraction comprised between both meshes. The pharmaceutical composition can be an oral composition, tablets, chewable tablets, or a powder for suspension in water.Type: ApplicationFiled: March 20, 2012Publication date: March 12, 2015Applicants: Eastbrand Holdings GMBH, Laboratorios Bago S.A.Inventor: Mario Atilio Los
-
Publication number: 20140107108Abstract: Disclosed is a composition comprising alprazolam for treating primary insomnia and insomnia associated with anxiety states and the corresponding use and method comprising the administration of alprazolam sublingual tablets having a disintegration time lower than 30 seconds and having the alprazolam preferably in non-crystalline or partially crystalline form according to the X-ray diffraction crystallography expanded for the position delta 9-12.5 (2 theta), to a patient suffering from said disorder. There is also disclosed a method for preparing a composition according to the invention, where the alprazolam is solved in a pharmaceutical acceptable solvent and a binder, preferably polyvinylpyrrolidone, is incorporated to the solution.Type: ApplicationFiled: December 11, 2013Publication date: April 17, 2014Applicant: Laboratorios Bago S.A.Inventor: Mario Atilio Los
-
Patent number: 8685449Abstract: Pharmaceutical compositions with anti-obesity activity that act peripherally are provided, which comprise a premixture made up of pure orlistat as the active ingredient and other components that afford the premixture stability and suitable physical properties for simply preparing compositions for oral use with convenient dosage flexibility; and optionally necessary thickening, flavouring and colouring agents. A method for preparing said compositions is also provided. The orlistat content in the premixture is less than 20% of the total weight of the mass, preferably between 12 and 17%. The pharmaceutical composition can be formulated indistinctively from the premixture both as grooved tablets and powder for suspension.Type: GrantFiled: February 1, 2010Date of Patent: April 1, 2014Assignees: Laboratorios Bago S.A., Eastbrand Holding GmbHInventor: Mario Atilio Los
-
Publication number: 20120294941Abstract: Pharmaceutical compositions with anti-obesity activity that act peripherally are provided, which comprise a premixture made up of pure orlistat as the active ingredient and other components that afford the premixture stability and suitable physical properties for simply preparing compositions for oral use with convenient dosage flexibility; and optionally necessary thickening, flavouring and colouring agents. A method for preparing said compositions is also provided. The orlistat content in the premixture is less than 20% of the total weight of the mass, preferably between 12 and 17%. The pharmaceutical composition can be formulated indistinctively from the premixture both as grooved tablets and powder for suspension.Type: ApplicationFiled: February 1, 2010Publication date: November 22, 2012Applicants: Eastbrand Holding GMBH, Laboratorios Bago S.A.Inventor: Mario Atilio Los
-
Patent number: 8093271Abstract: An anti-acid pharmaceutical composition for the rapid and prolonged neutralization of gastric acidity with mucosa-protecting activity in powder form to prepare, by dispersion in water, a pharmaceutical solution or suspension for oral use characterized in that the composition includes sodium alginate; an anti-acid soluble agent or a combination of anti-acids; an inhibitor of proton pump; diluent and sweetening agents, wherein a) at least 30% of sodium alginate present in the formulation along with the total of the inhibitor of proton pump are homogeneously distributed over the surface of the total soluble anti-acid agent of the combination of anti-acids of the composition; and b) the rest, about 70%, of sodium alginate present in the formulation contains a percentage of humidity of less than 2%.Type: GrantFiled: December 21, 2009Date of Patent: January 10, 2012Assignee: Laboratorios Bago S.A.Inventor: Mario Atilio Los
-
Patent number: 7968118Abstract: An anti-acid pharmaceutical composition for the rapid and prolonged neutralization of gastric acidity with mucosa-protecting activity in powder form to prepare, by dispersion in water, a pharmaceutical solution or suspension for oral use characterized in that the composition includes sodium alginate; an anti-acid soluble agent or a combination of anti-acids; an inhibitor of proton pump; diluent and sweetening agents, wherein a) at least 30% of sodium alginate present in the formulation along with the total of the inhibitor of proton pump are homogeneously distributed over the surface of the total soluble anti-acid agent of the combination of anti-acids of the composition; and b) the rest, about 70%, of sodium alginate present in the formulation contains a percentage of humidity of less than 2%.Type: GrantFiled: June 5, 2007Date of Patent: June 28, 2011Assignee: Laboratorios Bago S.A.Inventor: Mario Atilio Los
-
Publication number: 20100160382Abstract: An anti-acid pharmaceutical composition for the rapid and prolonged neutralization of gastric acidity with mucosa-protecting activity in powder form to prepare, by dispersion in water, a pharmaceutical solution or suspension for oral use characterized in that the composition includes sodium alginate; an anti-acid soluble agent or a combination of anti-acids; an inhibitor of proton pump; diluent and sweetening agents, wherein a) at least 30% of sodium alginate present in the formulation along with the total of the inhibitor of proton pump are homogeneously distributed over the surface of the total soluble anti-acid agent [or] of the combination of anti-acids of the composition; and b) the rest, about 70%, of sodium alginate present in the formulation contains a percentage of humidity of less than 2%.Type: ApplicationFiled: December 21, 2009Publication date: June 24, 2010Applicant: LABORATORIOS BAGO S.A.Inventor: Mario Atilio Los
-
Publication number: 20090197873Abstract: Disclosed is a composition comprising alprazolam for treating primary insomnia and insomnia associated with anxiety states and the corresponding use and method comprising the administration of alprazolam sublingual tablets having a disintegration time lower than 30 seconds and having the alprazolam preferably in non-crystalline or partially crystalline form according to the X-ray diffraction crystallography expanded for the position delta 9-12.5 (2 theta), to a patient suffering from said disorder. There is also disclosed a method for preparing a composition according to the invention, where the alprazolam is solved in a pharmaceutical acceptable solvent and a binder, preferably polyvinylpyrrolidone, is incorporated to the solution.Type: ApplicationFiled: February 2, 2009Publication date: August 6, 2009Applicant: Laboratorios Bago S.A.Inventor: Mario Los
-
Patent number: 4332796Abstract: Potentiated sulfonamide compositions useful for intramuscular injection are disclosed which comprise mixtures of alkali metal sulfonamides with microcrystalline potentiators wherein the microcrystals have been coated with mixtures of phospholipids and non-ionic surfactants. The compositions are advantageous in that they can be used extemporaneously by addition of sterile water for injection, the resulting aqueous preparation is stable for long periods of time and upon use the compositions are characterized by syringeability and lack of irritation at the injection site.Type: GrantFiled: June 11, 1980Date of Patent: June 1, 1982Assignee: Laboratorios Bago S.A.Inventor: Mario A. Los
-
Patent number: 4277496Abstract: The disclosure is of a class or organic compounds and pharmaceutical compositions containing them as the active ingredient thereof, which are useful for the alleviation of pain and/or inflammation in mammals, including humans, suffering from pain and/or inflammation.Type: GrantFiled: May 13, 1980Date of Patent: July 7, 1981Assignee: Laboratorios Bago S.A.Inventor: Mario A. Los
-
Patent number: 4273777Abstract: The disclosure is of a class of organic compounds and pharmaceutical compositions containing them as the active ingredient thereof, which are useful for the alleviation of pain and/or inflammation in mammals, including humans, suffering from pain and/or inflammation.Type: GrantFiled: May 13, 1980Date of Patent: June 16, 1981Assignee: Laboratorios Bago S.A.Inventor: Mario A. Los
-
Patent number: 4256760Abstract: The disclosure is of a class of organic compounds and pharmaceutical compositions containing them as the active ingredient thereof, which are useful for the alleviation of pain and/or inflammation in mammals, including humans, suffering from pain and/or inflammation.Type: GrantFiled: June 4, 1979Date of Patent: March 17, 1981Assignee: Laboratorios Bago S.A.Inventor: Mario A. Los